The Use of In-Vitro Kinetic Models in the Evaluation of β-Lactam/β-Lactamase Inhibitor Combinations

  • Christine E. Thorburn
  • Brian Slocombe
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 349)


In conventional in vitro tests, bacteria are exposed to a constant concentration of antibiotic throughout the period of the test, and in the case of β-lactam/β-lactamase inhibitor combinations the concentrations of each component will be fixed. This does not reflect the situation in man, where the concentrations of antibiotic and inhibitor in the serum and tissues will be constantly changing according to absorption and elimination rates and any metabolism of the compounds. In vitro kinetic models can be used to simulate the concentrations of antibiotics measured in the serum and extravascular fluid of man following conventional dosage and to assess their antibacterial activities. In these studies, in vitro kinetic models have been used in various ways to assess the bactericidal activities of β-lactam/β-lactamase inhibitor combinations. Straightforward comparative studies can be carried out using different antibiotics; comparisons between different β-lactams and β-lactamase inhibitors; studies to look at concentrations of inhibitor required for different pathogens; and, interaction studies to look for synergy or antagonism can be carried out using these models. Examples of all these types of experiment are described below.


Kinetic Model Bactericidal Effect Clavulanic Acid Antagonistic Interaction Moraxella Catarrhalis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. Grasso, G. Meinardi, I. deCarneri, and V. Tamassia, New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity. Antimicrobial Agents and Chemother. 13:570–576 (1978).CrossRefGoogle Scholar
  2. 2.
    S.M. Harding, P.E.O. Williams, and J. Ayrton, Pharmacology of Cefuroxime as the 1-Acetoxyethyl ester in Volunteers, Antimicrob. Agents and Chemother. 25, 1:78–82 (1984).CrossRefGoogle Scholar
  3. 3.
    A. Glynne, R.A. Gouldbourn, and R. Ryden, A Human Pharmacology Study of Cefaclor, J. Antimicrob. Chemother. 4:343–348 (1978).PubMedCrossRefGoogle Scholar
  4. 4.
    G. Foulds, Pharmacokinetics of Sulbactam and Ampicillin in Humans — A Review. Reviews of Infect. Diseases 8. 5:S503–511 (1986).CrossRefGoogle Scholar
  5. 5.
    D.H. Staniforth, P.E. Coates, B.E. Davies, and R. Horton, Pharmacokinetics of Parenteral Ticarcillin Formulated with Clavulanic Acid — Timentin, Int. J. Clin. Pharm. Ther. and Toxic. 24, 3:123–129 (1986).Google Scholar
  6. 6.
    S.J. Cavaleiri, C.C. Sanders, and C. New, Influence of β-Lactamase Inhibitors on the Potency of Their Companion Drug with Organisms Possessing Class I Enzymes. Antimicrob. Agents and Chemother. 35, 7:1343–1347 (1991).CrossRefGoogle Scholar
  7. 7.
    A.R. White, D.H. Stokes, B. Slocombe, and R. Sutherland, Bactericidal Effects of Amoxycillin/Clavulanic Acid and Ticarcillin/Clavulanic Acid in In Vitro Kinetic Models, J. Antimicrob. Chemother. 15, A:227–232 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Christine E. Thorburn
    • 1
  • Brian Slocombe
    • 1
  1. 1.SmithKline Beecham PharmaceuticalsBetchworth, SurreyUK

Personalised recommendations